Article metrics

Download PDFPDF
Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis

 

Online download statistics by month:

Online download statistics by month: March 2019 to October 2024

AbstractFullPdf
Mar 2019400
Apr 20191400
May 20191801
Jun 20191600
Jul 20192802
Aug 20193201
Sep 20191400
Oct 20191800
Nov 2019200
Dec 20191000
Jan 20201600
Feb 20201001
Mar 2020602
Apr 2020600
May 20201600
Jun 20201001
Jul 20201600
Aug 2020402
Sep 20202002
Oct 20201401
Nov 20201200
Dec 20201403
Jan 20211801
Feb 20211801
Mar 20212002
Apr 2021202
May 2021200
Jul 2021101
Aug 2021001
Oct 20213000
Nov 2021801
Dec 20211400
Jan 20221902
Feb 2022800
Mar 20222300
Apr 2022800
May 20224100
Jun 20226100
Jul 20221600
Aug 20225000
Sep 20223600
Oct 20226000
Nov 20221200
Dec 20221600
Jan 20234000
Feb 20237200
Mar 2023800
Apr 20231000
May 2023800
Jun 20231000
Jul 20231600
Aug 2023800
Sep 20232400
Oct 20231600
Nov 20231200
Dec 20232600
Jan 2024200
Feb 20242200
Mar 20241300
Apr 20242000
May 20242301
Jun 20243800
Jul 20245401
Aug 20244200
Sep 20244201
Oct 20242001
Total1289031